March 13, 2026

iRadimed Corporation (IRMD) Stock Analysis: A 20.76% Upside in the Magnetic Healthcare Market

iRadimed Corporation (NASDAQ: IRMD) has carved out a niche in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $1.26 billion, iRadimed is a notable..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Powerhouse with a Potential 98% Upside

Praxis Precision Medicines, Inc (NASDAQ: PRAX) is making waves in the healthcare sector, specifically within the biotechnology industry, with its robust pipeline of therapies targeting central nervous system (CNS) disorders...

SI-BONE, Inc. (SIBN)

⚠️ No article content returned.

..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: High Revenue Growth Propels Interest Despite Challenging Valuation Metrics

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a burgeoning player in the biotechnology sector, has been capturing attention with its impressive revenue growth figures despite the complex dynamics of its financial..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Biotech Innovator with 43% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is carving a niche in the biotechnology sector with its pioneering approach to cancer treatment. Specializing in the development of small molecule inhibitors, the company..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Potential Upside of Over 100% with Strong Revenue Growth

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a commercial-stage biopharmaceutical company based in Chicago, Illinois, has been making waves in the healthcare sector. Focused on developing therapies for chronic endocrine and..

KalVista Pharmaceuticals (KALV) Stock Analysis: 95.63% Potential Upside Beckons Investors

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is making waves in the biotechnology sector with its promising pipeline of drug therapies aimed at addressing diseases with unmet medical needs. With a market..

uniQure N.V. (QURE) Stock Analysis: Exploring a 124% Upside Potential in the Biotechnology Sector

Investors with a keen eye on the biotechnology sector may want to turn their attention to uniQure N.V. (NASDAQ: QURE), a Netherlands-based firm making waves with its innovative approach to..

AbCellera Biologics Inc. (ABCL) Stock Report: Exploring a 164% Potential Upside

Investors with an eye on the biotechnology sector may find AbCellera Biologics Inc. (NASDAQ: ABCL) an intriguing prospect, especially given the stock’s potential upside of 164.17%. This Canadian biotech firm,..

Neuropace, Inc. (NPCE) Stock Analysis: Insights into a 40% Potential Upside in the Medical Device Market

Neuropace, Inc. (NPCE), a key player in the medical devices sector focusing on innovative solutions for drug-resistant focal epilepsy, is capturing attention with its impressive market potential. With a market..

Valneva SE (VALN) Stock Analysis: A 25% Upside Potential in the Biotechnology Sector

Valneva SE (NASDAQ: VALN), a French biotechnology firm specializing in the development and commercialization of vaccines for infectious diseases, presents a compelling case for investors seeking opportunities in the healthcare..

ArriVent BioPharma, Inc. (AVBP) Investor Outlook: Analyzing a Potential 67.83% Upside in a Promising Biotech

ArriVent BioPharma, Inc. (NASDAQ: AVBP) stands out in the healthcare sector as a beacon of innovation within the biotechnology industry. With a market capitalization of $1.07 billion, ArriVent is carving..

Kura Oncology, Inc. (KURA) Stock Analysis: Unveiling a 266% Potential Upside in the Biotech Frontier

For investors with an eye on the biotechnology sector, Kura Oncology, Inc. (NASDAQ: KURA) presents an intriguing prospect. With its focus on developing innovative cancer treatments, Kura stands at a..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a Potential 96.78% Upside in Biotech Innovation

Intellia Therapeutics, Inc. (NASDAQ: NTLA) stands at the forefront of the biotechnology industry with its pioneering work in genome editing treatments. As a clinical-stage company, Intellia is focused on developing..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a 333.89% Potential Upside in the Biotechnology Sector

Investors seeking opportunities in the biotechnology sector might want to consider LENZ Therapeutics, Inc. (NASDAQ: LENZ), a company making strides in the field of vision-improving therapies. With a market capitalization..

Simulations Plus, Inc. (SLP) Stock Analysis: Exploring a 100% Potential Upside in Healthcare Tech

Simulations Plus, Inc. (NASDAQ: SLP), a key player in the Healthcare sector, specializes in developing cutting-edge drug discovery and development software. The company is renowned for leveraging artificial intelligence and..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech Prospect with Nearly 92% Upside Potential

Trevi Therapeutics, Inc. (NASDAQ: TRVI) stands out in the biotechnology sector with a promising outlook for investors seeking growth opportunities in the healthcare industry. With a market capitalization of $1.44..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 373% Upside in the Biotech Sector

Anavex Life Sciences Corp. (NASDAQ: AVXL), a prominent player in the biotechnology sector, has been capturing investor attention with its ambitious pipeline geared towards tackling neurodegenerative diseases. With a current..

GH Research PLC (GHRS) Stock Analysis: Potential Upside of 152.90% Amid Strong Buy Ratings

Ireland-based GH Research PLC (NASDAQ: GHRS) is a promising player in the biotechnology industry, specializing in the development of innovative treatments for depression. With a market capitalization nearing the $1..

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Cannabis Market with 47% Revenue Growth

Cronos Group Inc. (NASDAQ: CRON) stands as a notable player in the burgeoning cannabis industry, with its headquarters rooted in Stayner, Canada. As a company engaged in the cultivation, production,..

Search

Funds

March 13, 2026

Search

Funds

March 13, 2026

FTSE 100

Funds